Evidence map›Paper›PMID 35269594›Full record

ReviewInternational journal of molecular sciences2022

Emerging Glycation-Based Therapeutics-Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors.

Naila Rabbani, Paul J Thornalley

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Review
  3. Optimization of a bis-imine scaffold as a glyoxalase I inhibitor: synthesis, SAR, and docking studies.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Discovery of Glycation-Derived Cross-links at Arginine.Journal of the American Chemical Society · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Naila RabbaniDepartment of Basic Medical Science, College of Medicine, Qatar University Health, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-5819-2506
Paul J ThornalleyDiabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar.ORCID 0000-0001-7659-443X
Hamad bin Khalifa University · QAQatar University · QA

Funding

Qatar Foundation QB14Qatar University QU-ERG-CMED-2020-1
6 · The paper itself

Abstract

The abnormal accumulation of methylglyoxal (MG) leading to increased glycation of protein and DNA has emerged as an important metabolic stress, dicarbonyl stress, linked to aging, and disease. Increased MG glycation produces inactivation and misfolding of proteins, cell dysfunction, activation of the unfolded protein response, and related low-grade inflammation. Glycation of DNA and the spliceosome contribute to an antiproliferative and apoptotic response of high, cytotoxic levels of MG. Glyoxalase 1 (Glo1) of the glyoxalase system has a major role in the metabolism of MG. Small molecule inducers of Glo1, Glo1 inducers, have been developed to alleviate dicarbonyl stress as a prospective treatment for the prevention and early-stage reversal of type 2 diabetes and prevention of vascular complications of diabetes. The first clinical trial with the Glo1 inducer,

Indexed as

AnimalsDiabetes Mellitus, Type 2Drug Therapy, CombinationEnzyme InductionGlutathioneGlycosylationHesperidinHumansInsulin ResistanceLactoylglutathione LyaseMiceMolecular StructureNeoplasms, ExperimentalObesityPyruvaldehydeResveratrolGlutathionehesperetinHesperidinLactoylglutathione LyasePyruvaldehydeResveratrolS-4-bromobenzylglutathione cyclopentyl diestercancer chemotherapydiabetesdicarbonyl stressglyoxalasemalariamethylglyoxalresveratrolSARS-CoV-2

Identifiers

PMID35269594
PMCPMC8910005
OpenAlexW4213429603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.